Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

At the heart of the event was Organon’s commitment to empowering women through access to safe and effective family planning ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, ...

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...